TY - JOUR
T1 - VGLL fusions define a new class of intraparenchymal central nervous system schwannoma
AU - Schmid, Simone
AU - Mirchia, Kanish
AU - Tietze, Anna
AU - Liu, Ilon
AU - Siewert, Christin
AU - Nückles, Jakob
AU - Schittenhelm, Jens
AU - Behling, Felix
AU - Snuderl, Matija
AU - Hartmann, Christian
AU - Brandner, Sebastian
AU - Paine, Simon M.L.
AU - Korshunov, Andrey
AU - Hasselblatt, Martin
AU - Coras, Roland
AU - Epari, Sridhar
AU - Stadelmann, Christine
AU - Zechel, Sabrina
AU - Simon, Michèle
AU - Wilson, Yelena
AU - Gianno, Francesca
AU - Lucas, Calixto Hope G.
AU - Zherebitskiy, Viktor
AU - Kaimaktchiev, Vassil B.
AU - Robinson, Lorraina
AU - Aldape, Kenneth
AU - Hoving, Eelco W.
AU - Tops, Bastiaan B.J.
AU - Perera, Ashwyn Augustine
AU - Göller, Pauline
AU - Hernáiz Driever, Pablo
AU - Wesseling, Pieter
AU - Koch, Arend
AU - Perry, Arie
AU - Sahm, Felix
AU - Jones, David T.W.
AU - Capper, David
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
PY - 2025/4/1
Y1 - 2025/4/1
N2 - Background. Intracerebral schwannomas are rare tumors resembling their peripheral nerve sheath counterparts but localized in the central nervous system (CNS). They are not classified as a separate tumor type in the 2021 World Health Organization classification. This study aimed to compile and characterize these rare neoplasms morphologically and molecularly. Methods. We analyzed 20 tumor samples by histology, RNA next-generation sequencing, DNA-methylation profiling, copy number analyses, and single-nucleus RNA sequencing (snRNA-seq). Clinical data, including age, sex, and disease progression, were collected. Magnetic resonance imaging (MRI) series were included when available. Results. All cases with tissue available for histology review (n = 13) were morphologically consistent with intracerebral schwannoma, but differed in their extent of glial fibrillary acidic protein staining. All (n = 20) shared DNA-methylation profiles distinct from other CNS tumors, as well as from Vestigial-like family (VGLL)-altered peripheral nerve sheath tumors. Most cases (n = 14/17) harbored fusions of either Vestigial-like family member 3 (VGLL3) or Vestigial-like Family member 1 (VGLL1) (CHD7::VGLL3 [n = 9/17] and EWSR1::VGLL1 [n = 5/17]). In 2 cases, the presence of a VGLL3 fusion was also confirmed by copy number analyses (n = 2/17). MRI (n = 4) showed well-defined, nodular tumors with strong, homogeneous enhancement and no diffusion restriction. Tumors were located throughout the neuroaxis (supratentorial [n = 15], infratentorial [n = 4], and spinal [n = 1]). snRNA-seq of a VGLL1-fused tumor indicated VGLL1 upregulation in 28.6% of tumor cells (n = 1). During a median follow-up of 1.8 years (range 3 months-9 years), none of the tumors recurred (n = 10). Conclusions. We identify and define a new benign tumor class, designated VGLL-altered intraparenchymal CNS schwannomas. These tumors feature VGLL alterations and a specific DNA-methylation profile, with schwannoma-like histopathology and CNS localization, akin to previously classified intracerebral schwannomas.
AB - Background. Intracerebral schwannomas are rare tumors resembling their peripheral nerve sheath counterparts but localized in the central nervous system (CNS). They are not classified as a separate tumor type in the 2021 World Health Organization classification. This study aimed to compile and characterize these rare neoplasms morphologically and molecularly. Methods. We analyzed 20 tumor samples by histology, RNA next-generation sequencing, DNA-methylation profiling, copy number analyses, and single-nucleus RNA sequencing (snRNA-seq). Clinical data, including age, sex, and disease progression, were collected. Magnetic resonance imaging (MRI) series were included when available. Results. All cases with tissue available for histology review (n = 13) were morphologically consistent with intracerebral schwannoma, but differed in their extent of glial fibrillary acidic protein staining. All (n = 20) shared DNA-methylation profiles distinct from other CNS tumors, as well as from Vestigial-like family (VGLL)-altered peripheral nerve sheath tumors. Most cases (n = 14/17) harbored fusions of either Vestigial-like family member 3 (VGLL3) or Vestigial-like Family member 1 (VGLL1) (CHD7::VGLL3 [n = 9/17] and EWSR1::VGLL1 [n = 5/17]). In 2 cases, the presence of a VGLL3 fusion was also confirmed by copy number analyses (n = 2/17). MRI (n = 4) showed well-defined, nodular tumors with strong, homogeneous enhancement and no diffusion restriction. Tumors were located throughout the neuroaxis (supratentorial [n = 15], infratentorial [n = 4], and spinal [n = 1]). snRNA-seq of a VGLL1-fused tumor indicated VGLL1 upregulation in 28.6% of tumor cells (n = 1). During a median follow-up of 1.8 years (range 3 months-9 years), none of the tumors recurred (n = 10). Conclusions. We identify and define a new benign tumor class, designated VGLL-altered intraparenchymal CNS schwannomas. These tumors feature VGLL alterations and a specific DNA-methylation profile, with schwannoma-like histopathology and CNS localization, akin to previously classified intracerebral schwannomas.
KW - VGLL
KW - gliofibroma
KW - glioma
KW - schwannoma
KW - tumor
KW - Prognosis
KW - Follow-Up Studies
KW - Humans
KW - Middle Aged
KW - Male
KW - Neurilemmoma/genetics
KW - Transcription Factors/genetics
KW - Brain Neoplasms/genetics
KW - Biomarkers, Tumor/genetics
KW - Young Adult
KW - DNA Methylation
KW - Nerve Tissue Proteins/genetics
KW - Adult
KW - Female
KW - Aged
KW - Oncogene Proteins, Fusion/genetics
UR - https://www.scopus.com/pages/publications/105005562429
UR - https://www.mendeley.com/catalogue/7ff878e8-c429-3764-9ce1-1ff06052b9f1/
U2 - 10.1093/neuonc/noae269
DO - 10.1093/neuonc/noae269
M3 - Article
C2 - 39713960
AN - SCOPUS:105005562429
SN - 1522-8517
VL - 27
SP - 1031
EP - 1045
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - 4
ER -